Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience.

Neth Heart J · 2017 · PMC5653537 · PMID 28913627

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Furthermore, and of more concern, the AIDA trial showed a highly significant difference in the rate of scaffold thrombosis [ 3 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.